BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

    Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

  • The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa MYLGeY5kfGmxbjDBd5NigQ>? NXTaT2F4OTEEoN88US=> NH;iOYsyNjViaB?= NF;DU4ti[m:uaYPo[ZMhSlCDIHnu[JVk\WRidYCgdoVofWyjdHnvckBw\iCITjDhcoQhVU2SLUpCpC=> MnPYNlU4QTd2M{e=
SiHa  NYD3c2VtTnWwY4Tpc44hSXO|YYm= NGH1[lgyOMLizszN NHPn[lUyNjViaB?= NHnxSYli[m:uaYPo[ZMhSlCDIHnu[JVk\WRidYCgdoVofWyjdHnvckBw\iCITjDhcoQhVU2SLUpCpC=> NFr5R4kzPTd7N{SzOy=>
ARPE-19 NWj1O5dvTnWwY4Tpc44hSXO|YYm= MXuxJO69VQ>? M2fjeFAvPSCq Mlfzd5VxeHKnc4Pld{BVTy2rbnT1Z4VlyqCLTD24xsBxem:vb4TldkBi[3SrdnH0bY9v NUi4cHRYOjV3OUOwNlk>
HCT116 NGfRZYlHfW6ldHnvckBCe3OjeR?= NGLwbmg2KM7:TR?= NH\oSXYzKGh? M3X4SWROW09? NVjLRWM2[XS2ZX71ZZRmeyC|aXz5cYFzcW5vaX7keYNm\CCmb4fudoVofWyjdHnvckBw\iCleXPsbY4hTDF? NGfMfGEzPTR5OUeyNy=>
HMECs MUTGeY5kfGmxbjDBd5NigQ>? MYG1xsDPxE1? MmHQNkBp MXfhZo9tcXOqZYOgWG5HNc7zLXnu[JVk\WRiVlPBUU0yKGW6cILld5Nqd28EoB?= MWmyOVE6OzFzNh?=
A549  NX7zV3I6TnWwY4Tpc44hSXO|YYm= NH\qUo0yOOLCidM1US=> NIPPNWUyOiCq MmDZd5VxeHKnc4Pld{BFfmxvMzDpcoR2[2WmIHHjeIl3[XSrb36gc4YheDZ3 NUDXcIxPOjVzNU[4NFA>
RAW 264.7 MX3GeY5kfGmxbjDBd5NigQ>? M{TRTlXDqM7:TR?= M2GwSFEhcA>? MlHwbY5pcWKrdIOgWG5HNc7zIHHu[EBKVC1zMjDwOFAheHKxZIXjeIlwdg>? NV7FW2xNOjVyMUm1Olc>
macrophages Ml\XSpVv[3Srb36gRZN{[Xl? M3TTS|UhyrWP NUHkPJBEOyCq MmjldIFzfGmjbHz5JIJtd2OtczDZVGZUNWmwZIXj[YQh\XiycnXzd4lwdiCxZjDpUm9UKGGwZDDDU3guOsLi MWOyOFk3Pzh7OB?=
HUVECs NF\ZeHZHfW6ldHnvckBCe3OjeR?= MVKzMVMxKM7:TR?= MVWxJIg> M1vQNZJm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gcYlTNTF2NnGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXiyOFg3Ozl4NR?=
HeLa  NWjk[nFGTnWwY4Tpc44hSXO|YYm= NHnURVc2yqEQvF2= MWCyOEBp M2jleGROW09? M{eye5Jm\HWlZYOgeIhmKGGldHn2bZR6KG:oIGTOSk3PuSCycn;tc5RmesLi MUWyOFY2Pzd6Mx?=
A549 M{fIe2Z2dmO2aX;uJGF{e2G7 NIrVbFMyOCEQvF2= NEPO[o0y6oDLaB?= NXjG[o8ycW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJBpd3OyaH:tTe67Ss7zIHnuJHBCOTB|LXnu[oVkfGWmIHP1cJR2emW|wrC= NGDMV5czPDZzMkS4PC=>
HUVEC MoL3SpVv[3Srb36gRZN{[Xl? NIf2W4szOCEEtV2= MnLYNE42KGh? NUTrWItHTE2VTx?= MW\wdoV3\W62czD0bIUhcW6mdXP0bY9vKG:oIFXBUUBmgHC{ZYPzbY9v Mn72NlQ2PTF{MEm=
A549RT-eto NV3P[mhvSXCxcITvd4l{KEG|c3H5 MlqzNVDDqM7:TR?= NWrTfpZiOjRiaB?= MkT6SG1UVw>? Ml3NZYNk\WyncnH0[ZMhTkWUTz3t[YRq[XSnZDDhdI9xfG:|aYO= MUGyOFU{PTB6Mx?=
THP-1  M1rGfWZ2dmO2aX;uJGF{e2G7 MWmwMlEwOcLizszN NYDWdXR2OC53IHi= NYL3Z|JM[WK{b3fheIV{KFSQRj5OtUB{\WO{ZYTpc44h[XNid3XscEBieyC2aHWgbY5kemWjc3XkJJNm[3KndHnvckBw\iCLTD22JIFv\CCLTD2x{tI> M1H4dFI1Ozd6NUO2
SKCXCR2  MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiyJOK2VQ>? M{mzbVQ5KGh? M4LDWoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44he2mpbnnmbYNidnSueR?= MnTLNlQ{PzZ5NEe=
SKCXCR2  MlrLSpVv[3Srb36gRZN{[Xl? NIHGc5YzKML3TR?= NHnMcIM1QCCq NFnHVHVjdG:la4OgeIhmKEO[Q1yxMYlv\HWlZXSgZ4VtdCCrbo\hd4lwdg>? Ml3ENlQ{PzZ5NEe=
OVCXCR2 M2XERWZ2dmO2aX;uJGF{e2G7 MXKyJOK2VQ>? NETHV2c1QCCq NWfxVYVn[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25? NIHpV28zPDN5Nke0Oy=>
DSCs  MXfGeY5kfGmxbjDBd5NigQ>? MYOyMlUh|ryP MlHHNE42KGh? MV3y[ZZmenOnczD0bIUh\W6qYX7j[Y1mdnRib3[gR2NNOi:FQ2KyJIV5eHKnc4Ppc44hd2ZiRGPDd{BqdmS3Y3XkJIJ6KEmOLUOz NF;1T5czPDN2NEK0NC=>
WPs NFiwVXNHfW6ldHnvckBCe3OjeR?= M1zHelI2KM7:TR?= M4jp[lUhdWmw MWDzeZBxemW|c3XzJGFVWCCjbnSgendHKHOnY4LleIlwdg>? M4DOe|I1OzNzMkC3
A549RT-eto M{fiNWFxd3C2b4Ppd{BCe3OjeR?= M1jVO|ExyqEQvF2= NWPVbVd{OjRiaB?= NW\PVmtK[WOlZXzldoF1\XNiRkG0JIV5fHKjY4StcYVlcWG2ZXSgZZBweHSxc3nzJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIF[xOC=> M4fwVFI1OjJyN{K1
A549RT-eto MoDSSpVv[3Srb36gRZN{[Xl? NGjubmYyOMLizszN M1m0UVI1KGh? M2fpOIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gUmYu|rqEIHHu[EBRNWeywrC= NFfnTG4zPDJ{MEeyOS=>
FaDu MUPGeY5kfGmxbjDBd5NigQ>? NXXzPXBCOiCq MnnVbY5pcWKrdIOgdFY2KGW6cILld5Nqd25iYX7kJIJtd2OtczDUUmbPuS2rbnT1Z4VlKFSZSWPUJIV5eHKnc4Ppc44> NXfGbXRDOjR{MkC2NlI>
IVD  NWHqU4VzTnWwY4Tpc44hSXO|YYm= NH;OTGQyOMLizszN NHjnfGU{KGR? MlnJdoV3\XK|ZYOgWG5HNc7z4pETcYVlcWG2ZXSgd5VxeHKnc4Ppc44hd2ZidHjlJIRqe2NibXH0dol5KG2jY4LvcY9t\WO3bHXzJIFo\3KnY3HuJIFv\CClb3zsZYdmdiCLSR?= MoDCNlQyPzZ6MEi=
IVD  MnLqSpVv[3Srb36gRZN{[Xl? MlzINVDDqM7:TR?= M4DSNVMh\A>? NYj6XZFs[WK{b3fheIV{KFSQRj5OtgKBm2mwZIXj[YQhfXBvcnXneYxifGmxbjDv[kBCTEGPVGOtOEBidmRiQVTBUXRUNTYEoB?= NULRU5p6OjRzN{[4NFg>
iNKT NWG3ZW14TnWwY4Tpc44hSXO|YYm= MorZNVAwOTByIN88US=> M1zSe|AvPSCq M1fFcolvcGmkaYTzJJRp\SCrbnT1Z5Rqd25ib3[gRVJCWiCvUl7BJIFv\CCxdHjldkBn[WO2b4K= M2LZRVI1OTJ2NEWz
PC-3 MUHGeY5kfGmxbjDBd5NigQ>? NUPsb|NCOi53L{WvNVAh|ryP NUXKWFdHOC53IHi= MXficI9kc3NiSVfGMWlKNWmwZIXj[YQhW1SVIH3SUmEh\XiycnXzd4lwdsLi NUG4RZdwOjRyNUW1NlA>
THP-1  M1S5TmZ2dmO2aX;uJGF{e2G7 M{OzOVExyqEQvF2= NGDGSWcyyqCq MXHhZo9tcXOqZYOgeIhmKGWoZnXjeEBw\iC{SGPQNlchd25iU2KtRUBuWk6D MVmyN|k{QTN7OB?=
A549 M3:2bWZ2dmO2aX;uJGF{e2G7 Mmm2NeKh|ryP M3;KRVQ5KGh? MnPy[Y5p[W6lZYOgeIhmKHWyLYLl[5Vt[XSrb36gc4YhUc78QjDhcoQhe3Wkc3XxeYVvfCCmZXPy[YF{\SCrbjDCZZgh\XiycnXzd4lwdiCrbnT1Z4VlKGK7IHPvcYJqdmWmIIP0bY12dGG2aX;u NIL3eGYzOzlyMEC4NC=>
A549 MWfBdI9xfG:|aYOgRZN{[Xl? NV2xZ3g5OcLizszN M2\UW|Q5KGh? MmLLdoVlfWOnczD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IHPvcYJqdmWmIIP0bY12dGG2aX;u NEfYOlgzOzlyMEC4NC=>
NCI-N87 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[yRYsyOC9{MD:zNEDPxE1? MXK2M|I1KGh? MVnzeZBxemW|c3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NVSxW4pIOjN6NE[1OFU>
AGS NE\ucGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO5NlYyOC9{MD:zNEDPxE1? NUSxfJE5Pi9{NDDo MmHid5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NXK1dmZROjN6NE[1OFU>
MGC80-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjVNVAwOjBxM{Cg{txO Ml;vOk8zPCCq MXLzeZBxemW|c3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MnfFNlM5PDZ3NEW=
HGC-27  MmXaSpVv[3Srb36gRZN{[Xl? NXz4S2E6Py53L{G1M|MxKM7:TR?= NIi3O|Q3KGh? NHHZ[YhqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCjbnSgeZAuemWpdXzheIlwdiCxZjDJ{tpD|rF? NFGwdJEzOzh2NkW0OS=>
MGC80-3 NXLqN3JFTnWwY4Tpc44hSXO|YYm= M1PkNVcvPS9zNT:zNEDPxE1? MW[2JIg> NHnXSHdqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCjbnSgeZAuemWpdXzheIlwdiCxZjDJ{tpD|rF? Mn;xNlM5PDZ3NEW=
HGC-27  Ml;XRZBweHSxc3nzJGF{e2G7 MkDsO{42NzF3L{OwJO69VQ>? MlfHOkBp NY\IWpQ5cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NXnGRXRyOjN6NE[1OFU>
HBE  NGW1R|lHfW6ldHnvckBCe3OjeR?= M3vCTFEx|ryP M4rJZlNp NXTPTlh{[WKxbHnzbIV{KHSqZTDpcoNz\WG|ZYOgc4YhUUxvNjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhS1OH M3nTbVI{QDJ2MEi5
HepG2 Ml;uSpVv[3Srb36gRZN{[Xl? Mn\oNE4{NzFxMzFOwG0> MWm0PEBp MkHTdoVlfWOnczDJUFYucW6mdXPl[EBRV05zIHX4dJJme3Orb36= MnzXNlM4QTF6M{O=
THP-1 Mmi0SpVv[3Srb36gRZN{[Xl? MYK1JOK2VQ>? MWOxJIg> MmDzSG1UVw>? M1y0dolvcGmkaYTzJG1VSi2rbnT1Z4VlKE6IzsrCJIFkfGm4YYTpc44> NHjlVFkzOzZ|NEKxPC=>
THP-1  MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7zW4VqPSEEtV2= MnnlOE85KGR? MUPEUXNQ NELMRWFz\WS3Y3XzJJRp\SC4aXHibYxqfHlib3[gbY51emGlZXzseYxiesLiTWTC NE\GcW0zOzZ|NEKxPC=>
MDM MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu1JOK2VQ>? MljMOE85KGR? MVnEUXNQ MUHy[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE MkC2NlM3OzR{MUi=
AM M3PMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW1JOK2VQ>? NGjDWJg1NzhiZB?= Mnz6SG1UVw>? Ml\DdoVlfWOnczD0bIUhfmmjYnnsbZR6KG:oIHnueJJi[2WubIXsZZLDqE2WQh?= NHfI[5QzOzZ|NEKxPC=>
RAW 264  MY\GeY5kfGmxbjDBd5NigQ>? NH70TXkxNjJvNTFCuW0> MkLmN|AwPjBxOUCgcYlv NI\6elRqdmirYnn0d{B1cGVicHjvd5Bp[XSjc3WgZYN1cX[rdImgc4YhWFSSMVNCpC=> M2LnSVI{PTd6M{Cy
HUVEC NVPvN2V[TnWwY4Tpc44hSXO|YYm= M4rWU|ExyqEQvF2= NU[0bpBmOC53IHi= MVrEUXNQ M1P5PYNwfW62ZYLhZ5RmeyC2aHWgcI9{eyCxZjDUbYUzKG2UTlG= NFK3fIkzOzV4M{[zNi=>
HT29 NH3X[HFHfW6ldHnvckBCe3OjeR?= NHP4ZmYyOC9|MD:xNFAh|ryP NFq4OJgyKGh? MmDibY5pcWKrdHXzJIJwfGhiVGfFRWsucW6mdXPl[EBxOTByIIDyc4Nme3Orbne= NIHJZ20zOzV{N{G1OC=>
HT29 M{jHTGZ2dmO2aX;uJGF{e2G7 Mo\RNVAwOzBxMUCwJO69VQ>? M1jybVEhcA>? NGXpNHlqdmirYnn0d{BVVkZvaX7keYNm\CCyaH;zdIhwenmuYYTpc44h[W6mIHTl[5Ji\GG2aX;uJI9nKEoQulNOtS=> M4\QT|I{PTJ5MUW0
MM.1S M1LQ[GFxd3C2b4Ppd{BCe3OjeR?= NF;PcJc{OCEEtV2= M13pfFMhcA>? NITQPHhqdmS3Y3XzJG1OKGOnbHyg[IVifGhiaX72c4x3\XNibnXjdo9{cXN? NXPpeJZkOjN3MkexOVQ>
KMS-12-BM NYHIdJNrSXCxcITvd4l{KEG|c3H5 MVuzNEDDvU1? M{nvOlMhcA>? MmS0bY5lfWOnczDNUUBk\WyuIHTlZZRpKGmwdn;seoV{KG6nY4Lvd4l{ NH\uU40zOzV{N{G1OC=>
BAFs M1T1[2Z2dmO2aX;uJGF{e2G7 NFW5b2gxNjVxMdMg{txO NULvWnBqOjRiaB?= MV\pcohq[mm2czDUUmbPuS:GRWigbY5lfWOnZDDDXXAyQUFzwrD0doFve2O{aYD0dy=> NV\ubnVJOjN2OEW0OVc>
SP6.5 MWDGeY5kfGmxbjDBd5NigQ>? M2nnRlUh|ryP NWDmboV2OiCq M1q4UIRm[3KnYYPld:KhfHKjboPsc4NifGmxbjDv[kBxPjViaX6geIhmKG63Y3zleZPDqA>? NHPPZVAzOzR2M{C4Oi=>
VUP MWTGeY5kfGmxbjDBd5NigQ>? M3PmWFUh|ryP M3fKNFIhcA>? NFLuWWhl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB? M2rDVlI{PDR|MEi2
OCM1 M1;3OWZ2dmO2aX;uJGF{e2G7 M{joSFUh|ryP Mn;GNkBp M3j4bYRm[3KnYYPld:KhfHKjboPsc4NifGmxbjDv[kBxPjViaX6geIhmKG63Y3zleZPDqA>? NInYU5AzOzR2M{C4Oi=>
OM431 NHTwSZNHfW6ldHnvckBCe3OjeR?= MYi1JO69VQ>? M1q2eVIhcA>? MkDx[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh NHPxOIYzOzR2M{C4Oi=>
SP6.5 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLHNk42NTJyIN88US=> MXOyOEBpyqB? NFLBUoxKSzVyPUWg{txONCCneHjpZol1eyC|dILvcoch[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeJMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWPZ[29WOjN2NEOwPFY>
VUP MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nlfFIvPS1{MDFOwG0> MkfKNlQhcMLi MUHJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmjTNlM1PDNyOE[=
OCM1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELNZXczNjVvMkCg{txO M4TsUVI1KGkEoB?= Mm\zTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4e2N|I{PDR|MEi2
OM431 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKxS5ozNjVvMkCg{txO MlzNNlQhcMLi M{TVdmlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkDrNlM1PDNyOE[=
SP6.5 NVXMb5RjSXCxcITvd4l{KEG|c3H5 NXTXdnczPSEQvF2= M33n[FI1KGkEoB?= MX\pcoR2[2W|IHHwc5B1d3Orc9Mg NUTlRZRPOjN2NEOwPFY>
VUP MmrQRZBweHSxc3nzJGF{e2G7 M37uU|Uh|ryP NEPiPFgzPCCqwrC= NEWxNZdqdmS3Y3XzJIFxd3C2b4Ppd:Kh MoLUNlM1PDNyOE[=
OCM1 MkXSRZBweHSxc3nzJGF{e2G7 NYDRTmFOPSEQvF2= NGXSd|gzPCCqwrC= NELDRpFqdmS3Y3XzJIFxd3C2b4Ppd:Kh NHy1UVkzOzR2M{C4Oi=>
OM431 NG\ZNZNCeG:ydH;zbZMhSXO|YYm= NHfSNlI2KM7:TR?= MUKyOEBpyqB? MWLpcoR2[2W|IHHwc5B1d3Orc9Mg M3frOFI{PDR|MEi2
SP6.5 NEnOS49HfW6ldHnvckBCe3OjeR?= NX3LUZlxPSEQvF2= NIm0b48yOiCq M{\lR5Jm\HWlZYOgeIhmKG2rZ4LheIlwdsLi M1;NdVI{PDR|MEi2
VUP M1HHUmZ2dmO2aX;uJGF{e2G7 MVi1JO69VQ>? MXexNkBp M4nxXZJm\HWlZYOgeIhmKG2rZ4LheIlwdsLi NUPnVVNVOjN2NEOwPFY>
OCM1 M3y0fmZ2dmO2aX;uJGF{e2G7 MXK1JO69VQ>? M4LkclEzKGh? NFTE[4Fz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= NXjWNIhDOjN2NEOwPFY>
OM431 M3;W[mZ2dmO2aX;uJGF{e2G7 NV\HcolRPSEQvF2= MXSxNkBp MkHIdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? MYCyN|Q1OzB6Nh?=
HBL-1  NGjafFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7LN:Kh|ryP Mke2NlQwPDhxN{KgbC=> M4DhO2ROW09? Ml3nd4xwf3NiY3XscEBoem:5dHigcY9l\XO2bIm= M4[2blI{PDRzN{Ow
RAW 264.7 NXLsV|I2TnWwY4Tpc44hSXO|YYm= NYn0ZW93Oi1zNTFOwG0> NET0RpgyKGh? MkLxSG1UVw>? NFPuW2h{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKEmNSzDmZY1qdHlibXXtZoVzew>? NGewNWYzOzR2MUezNC=>
IL-1R  NInIZWpHfW6ldHnvckBCe3OjeR?= M1OwflIuOTVizszN MWOxJIg> NGe4U4dFVVOR NUDX[WhXe3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCLS1ug[oFucWy7IH3lcYJmenN? MoC0NlM1PDF5M{C=
RAW 264.7 M1P6ZWZ2dmO2aX;uJGF{e2G7 NEX1XmYyPSEQvF2= MWSxJIg> NEnZV4VFVVOR NFm1R21{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms> MkXKNlM1PDF5M{C=
IL-1R  NWXvbXg2TnWwY4Tpc44hSXO|YYm= M4DpWFE2KM7:TR?= NY[2N5VDOSCq NYDKbmdRTE2VTx?= MkX0d5VxeHKnc4Pld{B1cGViYXP0bZZifGmxbjDv[kBidmRiSl7L NFTzTmYzOzR2MUezNC=>
U2OS M1jZSmZ2dmO2aX;uJGF{e2G7 MknVNVUh|ryP M1PZOlEhcA>? MWfEUXNQ NYCwT2pYeHKndnXueJMhfGinIFzQV{0hd3JiSVytNU1{fGmvdXzheIVlKG[xcn3heIlwdiCxZjDLOlMueFWkIHPoZYlve8Li NGTSdFMzOzR2MUezNC=>
MT‐1  MYDGeY5kfGmxbjDBd5NigQ>? MUS4xsDDvW1? NX3k[IJ4OyCq M1HXTYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIIFihLBUXEGWMzDhcoQheOLCkETFRnAy MYiyN|I4QDR5OR?=
MT‐2  MkT6SpVv[3Srb36gRZN{[Xl? MlSyPOKhyrWv MmjMN{Bp Ml3s[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicPMAlHNVSVR|IHHu[EBx6oDSNFXCVFE> M{P6XVI{Ojd6NEe5
MT‐1  NXrOVJlqTnWwY4Tpc44hSXO|YYm= NFe5[Iw5yqEEtX2= MY[zJIg> M1XJcIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBxPjVic4XieY5qfCCxZjDOSwKBmM78QtMg NEjLUZEzOzJ5OES3PS=>
MT‐2  M1fxT2Z2dmO2aX;uJGF{e2G7 MkT5POKhyrWv NFq0OHE{KGh? NXGzOI5u\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKHB4NTDzeYJ2dmm2IH;mJG5H6oDSzsrCxsA> M37nWlI{Ojd6NEe5
MCF-7  M{TKdGZ2dmO2aX;uJGF{e2G7 NVj5[YZbOi53LUG1JO69VQ>? NELRUpYxNjViaB?= MlW2SG1UVw>? MULjZZV{\XNidHjlJIdz[WS3YXygcI9{eyCxZjDj[YxtKGGmaHXzbY9v NWLBWo9UOjNyOUOyNlc>
HaCaT  M1fLbGZ2dmO2aX;uJGF{e2G7 NYrkZm92PS5ywrFOwG0> MVKxxsBpyqB? MVfheJRmdnWjdHXzJJRp\SCWQ1;IMYlv\HWlZXSgdJJw\HWldHnvckBw\iCLTD22xsA> M3Wwe|I{ODRzMU[4
A549  MWPGeY5kfGmxbjDBd5NigQ>? M{XTTFEhcA>? NFrOS41qdmirYnn0d{BNXEFvaX7keYNm\CCVUD3BJI1TVkFicILv[JVkfGmxbtMgd4lodmmoaXPhcpRtgQ>? M4LY[VI{ODNzMkGz
OA chondrocytes  M3\BdGZ2dmO2aX;uJGF{e2G7 M2HwS|ExKM7:TR?= M4DuU|EhcA>? NU[xN5hi[myxY3vzJJRp\SCDR1WtRnNCNWmwZIXj[YQh\2WwZT;wdo91\WmwIHX4dJJme3Orb36gc4YhT1KSN{igc5IhS0:[LUKgLJA9OC5yNTm= NF[4RYQzOjl6MkKyPC=>
RAW264.7 NWHsSIxPTnWwY4Tpc44hSXO|YYm= M4DTOlE2KM7:TR?= MUWxOU0yOjBibXnu NHXT[4NjdG:la4OgeIhmKHC{b3T1Z5Rqd25ib3[gUm8tKFCJRUKsJIFv\CCWTl[t{tE> NYrNVW5LOjJ5NEW1NlM>
RAW264.7 M4C2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTydXFoPS1|MDFOwG0> MVuyOEBp NUKxSYhHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYDL[FU6OjJ5NEW1NlM>
HBL6 MWrBdI9xfG:|aYOgRZN{[Xl? NVHyWZVKOC53L{WvNlUh|ryP NXSzfoxEPi9{NDDo MoW3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHu[EBt\WWjZIOgeI8h[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzyqB? MVKyNlA4PDh{MB?=
HT29  M4O0WmZ2dmO2aX;uJGF{e2G7 Mm[xNU0yOCEQvF2= MVuxNOKhcA>? NXXFcGdtcW6lcnXhd4V{KEiRLUGgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NXSwWFQ{OjF4MkC5OlQ>
Ca9–22 NV:0U41vSXCxcITvd4l{KEG|c3H5 NIrrNFQyOMLizszNxsA> NI\ZVlYyKGh? M174SoNwdXCuZYTlcJkhcW6qaXLpeJMhSUyDLWDEWE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NWHXWFFnOjFzM{i0PFA>
Ca9–22 Moi5SpVv[3Srb36gRZN{[Xl? NXviUVlbOTEEoN88UeKh MVOxJIg> Mnu0Z49ueGyndHXsfUBi[nKxZ3H0[ZMhfGinIFHMRU1RTFRvaX7keYNm\CCMTlugZYN1cX[jdHnvci=> MUGyNVE{QDR6MB?=
A-549 NWHhTXBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jIeFExyqEQvF5CpC=> MYiyOE81QCCq MnHTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MVeyNFg3PjB2Mx?=
AP MU\GeY5kfGmxbjDBd5NigQ>? MkPLOU8yOCEQvF2= NYPNT4loPDhiaB?= Ml34[I94dnKnZ4XsZZRmeyC2aHWgRmFFKHC{b4TlbY4hdGW4ZXygZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoLBNlA2QTZ4NEW=
AQ1 M3ToPGZ2dmO2aX;uJGF{e2G7 MoDHOU8yOCEQvF2= Ml7JOFghcA>? NVPFZmx7\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVeyNFU6PjZ2NR?=
AP Mm\RSpVv[3Srb36gRZN{[Xl? NHXEVokzOCEQvF2= M3;Q[lQwQCCq M2G0bIRwf26{ZXf1cIF1\XNidHjlJGJCTCCycn;0[YlvKGyndnXsJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M1PHdlIxPTl4NkS1
AQ1 MWDGeY5kfGmxbjDBd5NigQ>? NUDycVRSOjBizszN Ml\tOE85KGh? M3ruPIRwf26{ZXf1cIF1\XNidHjlJGJCTCCycn;0[YlvKGyndnXsJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NVPlPWdWOjB3OU[2OFU>
THP-1 NFLT[2hHfW6ldHnvckBCe3OjeR?= NUL0UlFOPcLizszNxsA> NFWyZlcxNjViaB?= MlPWZZR1\W63YYTld{B1cGViTGDTMYlv\HWlZXSgdE1K|rqEzsGgdJJwfGWrbjDifUA4OiV? M1rUZVIxOzB7N{G4
K562 M4Tlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:yMVMxKM7:TR?= NVrGbm9sOjRiaB?= NIjHTGdKSzVyPUig{txONGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIHWUZUyQTZ2NkiwOy=>
Jurket MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ntUVIuOzBizszN NHjiengzPCCq M{\mOGlEPTB;Nz6xJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYnoeVFFOTl4NE[4NFc>
U937 NF3UOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHTNk0{OCEQvF2= M2S2PVI1KGh? MmTyTWM2OD1zMD61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEPZPI8yQTZ2NkiwOy=>
PBMC NYXn[mdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSyMVMxKM7:TR?= NFq5fWEzPCCq M{\1R2lEPTB;NECuNkDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mlf4NVk3PDZ6MEe=
K562 NUHBUHJ4SXCxcITvd4l{KEG|c3H5 Mn3oNk0zOMLizszNxsA> MUmyOEBp NHTjbIRqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZZBweHSxc3nz NWXlclYxOTl4NE[4NFc>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water <1 mg/mL
In vivo 5% DMSO+corn oil 8mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID